Financial PositionThe current cash position of Avalo is expected to fund operations into 2028, potentially supporting key value inflection points.
Market OpportunityThe HS market is rapidly expanding, with biologics projected to garner over $4 billion by 2035, which broadens the market opportunity for Avalo.
Product DifferentiationAVTX-009's potential for once-per-month administration could differentiate it from competitors in the same class.